Trial · NCT03467217
Results by group34
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 34
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Serum Alanine Aminotransferase (ALT) From Baseline. | Losartan Potassium Capsule | -5.3 | Standard Deviation 51.4 | U/L | |
| Change in Serum Alanine Aminotransferase (ALT) From Baseline. | Placebo Losartan Capsule | -6.3 | Standard Deviation 77.5 | U/L | |
| Change in Gamma-glutamyl Transpeptidase (GGT) Compared to Baseline | Losartan Potassium Capsule | -1.9 | Standard Deviation 13.9 | U/L | |
| Change in Gamma-glutamyl Transpeptidase (GGT) Compared to Baseline | Placebo Losartan Capsule | 0.6 | Standard Deviation 19.7 | U/L | |
| Change in Serum Aspartate Aminotransferase AST at 24 Weeks Compared to Baseline AST | Losartan Potassium Capsule | 0.2 | Standard Deviation 27.2 | U/L | |
| Change in Serum Aspartate Aminotransferase AST at 24 Weeks Compared to Baseline AST | Placebo Losartan Capsule | -4.5 | Standard Deviation 37.0 | U/L | |
| Relative Change in Serum Alanine Aminotransferase (ALT) Compared to Baseline ALT | Losartan Potassium Capsule | 2.7 | Standard Deviation 43.8 | percentage of change | |
| Relative Change in Serum Alanine Aminotransferase (ALT) Compared to Baseline ALT | Placebo Losartan Capsule | -5.7 | Standard Deviation 73.2 | percentage of change | |
| Change in ALT at 12 Weeks Compared to Baseline ALT | Losartan Potassium Capsule | -5.8 | Standard Deviation 43.0 | mg/dL | |
| Change in ALT at 12 Weeks Compared to Baseline ALT | Placebo Losartan Capsule | -19.3 | Standard Deviation 38.5 | mg/dL | |
| Change in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) Compared to Baseline. | Losartan Potassium Capsule | 4.5 | Standard Deviation 8.1 | mg/dL x uU/mL/405 | |
| Change in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) Compared to Baseline. | Placebo Losartan Capsule | 1.1 | Standard Deviation 5.2 | mg/dL x uU/mL/405 | |
| Change in Weight at 24 Weeks Compared to Baseline | Losartan Potassium Capsule | 4.4 | Standard Deviation 4.2 | kg | |
| Change in Weight at 24 Weeks Compared to Baseline | Placebo Losartan Capsule | 3.9 | Standard Deviation 4.3 | kg | |
| Change in Body Mass Index (BMI) at 24 Weeks Compared to Baseline. | Losartan Potassium Capsule | 0.8 | Standard Deviation 1.2 | kg/m^2 | |
| Change in Body Mass Index (BMI) at 24 Weeks Compared to Baseline. | Placebo Losartan Capsule | 0.8 | Standard Deviation 1.3 | kg/m^2 | |
| Change in Waist Circumference at 24 Weeks Compared to Baseline | Losartan Potassium Capsule | 2.6 | Standard Deviation 5.4 | cm | |
| Change in Waist Circumference at 24 Weeks Compared to Baseline | Placebo Losartan Capsule | 0.1 | Standard Deviation 6.4 | cm | |
| Change in Waist-to-hip Ratio at 24 Weeks Compared to Baseline | Losartan Potassium Capsule | 0.01 | Standard Deviation 0.05 | ratio | |
| Change in Waist-to-hip Ratio at 24 Weeks Compared to Baseline | Placebo Losartan Capsule | -0.01 | Standard Deviation 0.06 | ratio |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03467217/results